# AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

> **NCT00606476** · PHASE2 · TERMINATED · sponsor: **JANSSEN Alzheimer Immunotherapy Research & Development, LLC** · enrollment: 194 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Bapineuzumab (AAB-001)

## Key facts

- **NCT ID:** NCT00606476
- **Lead sponsor:** JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2013-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606476, "AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00606476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*